// App-Quantinova.ai

: Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

Researchers

Presenter

  • Saby George

Principal Investigators

  • James Larkin

  • Kateryna Chepynoga

  • Daniel Sharpe

  • Tuli De

  • Matthew Dyer

  • Flavia Ejzykowicz

  • Jessica May

  • Murat Kurt

Medical Centers

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Bristol-Myers Squibb, Uxbridge, United Kingdom

  • Parexel international, Billerica, MA

  • Parexel, Hørsholm, Denmark

  • Bristol-Myers Squibb Research, Princeton, NJ

  • Parexel, Uxbridge, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • Denmark

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved